TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03274284

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: chemoradiation
Description: chemoradiation in case of T1G3 BC after BCG failure.
Study: NCT01233804

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opting Out
Description: Usual care is for pregnant women to sign a consent to get the influenza vaccine. The intervention is to offer a group of women the option to sign only when they refuse the influenza vaccine.
Study: NCT01187017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 125 mg/m squared
Study: NCT01571102

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapy
Description: week 1 - 4: 3 times/week, week 5 - 8: 2 times/week, duration 40min.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise therapy
Description: week 1 - 4: 3 times/week, week 5 - 8: 2 times/week, duration 30 min.
Study: NCT00524485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aminolevulinic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aminolevulinic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aminolevulinic acid

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser therapy
Study: NCT04306471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months.
Description: The study subjects randomized to the treatment study arm will receive monthly subcutaneous injections of evolocumab 420 mg in the abdomen, thigh or upper arm. The study drug (evolocumab) prefilled injector pens are to be provided by Amgen.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1 milliliter (mL) Injector Pen x 3 monthly for 12 months
Description: The study subjects randomized to the control study arm will receive monthly subcutaneous injections of placebo 1 mL x 3 in the abdomen, thigh or upper arm. The study placebo prefilled injector pens are to be provided by Amgen.
Study: NCT02359318

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resin infiltration
Description: Resin infiltration is done according to manufactures´ instructions after de-bonding of old brackets and prior bonding of new brackets.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bonding and debonding of brackets.
Description: Brackets (Gemini metal brackets (3M Unitek) are bonded and de-bonded by one clinician (Roberto Vogel) and using the same bonding and de-bonding techniques and materials for all patients. All brackets were finally de-bonded at the end of the treatment, with silicon impressions taken before adhesive removal.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bonding and debonding of brackets.
Description: Brackets (Gemini metal brackets (3M Unitek) are bonded and de-bonded by one clinician (Roberto Vogel) and using the same bonding and de-bonding techniques and materials for all patients. All brackets were finally de-bonded at the end of the treatment, with silicon impressions taken before adhesive removal.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bonding and debonding of brackets.
Description: Brackets (Gemini metal brackets (3M Unitek) are bonded and de-bonded by one clinician (Roberto Vogel) and using the same bonding and de-bonding techniques and materials for all patients. All brackets were finally de-bonded at the end of the treatment, with silicon impressions taken before adhesive removal.
Study: NCT03481478

Intervention type: DIAGNOSTIC_TEST
Intervention: CT and MRI
Description: For such patients, using CT and/or MRI to find if existing humeral surgical neck fractures.

Intervention type: DIAGNOSTIC_TEST
Intervention: CT and MRI
Description: For such patients, using CT and/or MRI to find if existing humeral surgical neck fractures.
Study: NCT04605601

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality treatment
Description: Tennis, boxing, and baseball games of the Wii Sports package sre used for activating the upper extremity functions of the patients. In the tennis game, patients represent people holding rackets.

Intervention type: OTHER
Group type: OTHER
Intervention: conventional physiotherapy
Description: As the conventional physiotherapy, neuromuscular electrical stimulation and strengthening exercises for the deltoid, infraspinatus, triceps, biceps, supinator, and wrist extensor muscles, and passive, active, active assistive joint Rage of Motion, and stretching exercises for the shoulder, elbow and wrist joints are applied to the patients in the standardized program for the upper extremity in 10 repetitions.
Study: NCT00683436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adipiplon
Description: bilayer tablets 6 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambien CR
Description: Ambien CR 12.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adipiplon
Description: bilayer tablets 9 mg
Study: NCT01153386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil diethanolamine
Description: Treprostinil diethanolamine sustained release oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil diethanolamine
Description: Treprostinil diethanolamine sustained release oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil diethanolamine
Description: Treprostinil diethanolamine sustained release oral tablets.
Study: NCT01994252

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical therapy plus ICD

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical therapy plus CRT/ICD
Study: NCT04410497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Porcine xenograft (wound dressings)
Description: commercial porcine xenograft, derived from acellular dermis from porcine.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Silver foam (wound dressings)
Description: commercial silver containing foam dressing
Study: NCT03382132

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: momHealth
Description: Mobile health program delivered via an iPad. Program delivers information and support related to breastfeeding education, Ten Steps of the Baby Friendly Hospital Initiative, healthy eating and active living topics, and depression prevention information.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Participants will receive standard health care via their prenatal provider, including routine prenatal education and postpartum support.
Study: NCT01009060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK239512
Description: Histamine H3 Antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match GSK239512
Study: NCT01304264

Intervention type: DEVICE
Intervention: Color Doppler Imaging
Description: Color Doppler imaging (CDI) system for measurements of blood flow in the ophthalmic (OA), central retinal (CRA), and nasal (NPCA) and temporal (TPCA) posterior ciliary arteries. In each vessel, peak systolic velocity (PSV) and end diastolic velocity (EDV) were determined, and Pourcelot's resistive index will be calculated (RI = (PSV-EDV)/PSV).
Study: NCT02212639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: digoxin
Description: All patients will receive Digoxin without interruption. Doses can be modified individually to reach a serum drug concentration of 0.6 to 1.2 ng/ml for patients \<75 years and between 0.5-0.8 ng/ml in patients older than 75 years
Study: NCT01293903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qiliqiangxin capsule
Description: Qiliqiangxin capsule is administrated based on the standard heart failure treatment in China. Dosage: 1.2g/times. Frequency: 3 times/day. Duration: The whole study period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, similar in color and taste to Qiliqiangxin capsule, is administrated based on the standard heart failure treatment in China. Dosage: 1.2g/times. Frequency: 3 times/day. Duration: The whole study period.
Study: NCT03691493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Given PO
Study: NCT03539406

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCB-NK cells
Description: Intraperitoneal allogeneic UCB-NK cells infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCB-NK cells
Description: Intraperitoneal allogeneic UCB-NK cells infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Cyclofosfamide/fludarabine treatment
Study: NCT01628146

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SUPRACOR LASIK treatment
Description: The SUPRACOR algorithm uses the subjective refraction of the eye to create a treatment for the distance vision correction.
Study: NCT02005549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 15 mg/kg iv on Day 1 of each 3-week cycle, 5 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 75 mg/m2 on Day 1 of each 3-week cycle, 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: 950 mg/m2, orally twice daily, evening of Day 1 until morning of Day 15, followed by a 7 day rest period, every 3 weeks
Study: NCT00388986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GK Activator (2)
Description: 100mg po bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GK Activator (2)
Description: 100mg po bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide
Description: 10-20mg po daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide
Description: 10-20mg po daily
Study: NCT05680714

Intervention type: OTHER
Intervention: Implement coordination of care with multifactorial falls- and fracture risk assessment and tailored intervention
Study: NCT03617562

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Superior Capsular Reconstruction
Description: Residual rotator cuff defect is reconstructed with a dermal allograft secured to the glenoid and humeral head.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial Repair
Description: Rotator cuff is repaired with residual defect remaining.
Study: NCT04187898

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eflapegrastim
Description: Administered in Cycle 1, 30 minutes after TC chemotherapy.~Administered in Cycles 2-4, on day 2 of each cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eflapegrastim
Description: Administered in Cycle 1, 3 hours after TC chemotherapy.~Administered in Cycles 2-4, on day 2 of each cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eflapegrastim
Description: Administered in Cycle 1, 5 hours after TC chemotherapy.~Administered in Cycles 2-4, on day 2 of each cycle.
Study: NCT03646591

Intervention type: DRUG
Intervention: Chemotherapy
Description: Patients will receive four cycles of the standard dose of FLOT chemotherapy prior to curative gastrectomy. And four cycles of the FLOT chemotherapy is recommended after surgery. Preventive antiemetic and dexamethasone are allowed before chemotherapy, growth factor, or other supportive medicines are allowed for treatment only. Surgical intervention is allowed for acute bleeding or other surgical emergencies.
Study: NCT04187898

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eflapegrastim
Description: Administered in Cycles 1-4, 30 mins after TC chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m\^2 IV infusion.~Administered on Day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m\^2 IV infusion.~Administered on Day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m\^2 IV infusion.~Administered on Day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m\^2 IV infusion.~Administered on Day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m\^2 IV infusion.~Administered on Day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m\^2 IV infusion.~Administered on Day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m\^2 IV infusion.~Administered on Day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m\^2 IV infusion.~Administered on Day 1 of each cycle.
Study: NCT00287898

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Genetic Counseling
Description: Participants will receive all genetic counseling via telephone

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: subjects will receive standard in-person genetic counseling
Study: NCT02251015

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: occlusal plate
Description: In the plate group arm, the patients used the occlusal splints for all night plus 4 hours during the day and they made therapeutic exercises 15 repetitions 3 times a day.~The orientation for therapeutic exercises seek to correctly position the jaw in the resting position (maxillary teeth approximately 2mm away from the mandibular teeth and the tip of the tongue accommodated on top of the incisive papilla on the hard palate, beyond an exercise that consisted of repeated opening and closing movements paying close attention to the position of the tongue, the point of which being accommodated on the incisive papilla during the exercises. The patient was instructed to perform 15 repetitions 3 times a day.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic exercises
Description: The orientation for therapeutic exercises seek to correctly position the jaw in the resting position (maxillary teeth approximately 2mm away from the mandibular teeth and the tip of the tongue accommodated on top of the incisive papilla on the hard palate, beyond an exercise that consisted of repeated opening and closing movements paying close attention to the position of the tongue, the point of which being accommodated on the incisive papilla during the exercises. The patient was instructed to perform 15 repetitions 3 times a day.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic exercises
Description: The orientation for therapeutic exercises seek to correctly position the jaw in the resting position (maxillary teeth approximately 2mm away from the mandibular teeth and the tip of the tongue accommodated on top of the incisive papilla on the hard palate, beyond an exercise that consisted of repeated opening and closing movements paying close attention to the position of the tongue, the point of which being accommodated on the incisive papilla during the exercises. The patient was instructed to perform 15 repetitions 3 times a day.
Study: NCT02163902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-101
Description: Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements, recording of adverse events

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements, recording of adverse events
Study: NCT02536612

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lottery
Description: Opportunity for entry in lottery (each time, at months 3 and 6).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Lottery
Description: Transport compensation for study visits at baseline and at months 3 and 6. No chance to win lottery ticket.
Study: NCT05414461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combinations
Description: PD-1 inhibitor-based combinaiton treatment
Study: NCT01811771

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shanchol vaccine
Description: Shanchol vaccine contains whole cell inactivated heat killed and formalin killed bacteria consisting of 600 ELISA Units (EU) of lipopolysaccharide (LPS). It consists of formalin-killed V. cholerae Inaba, El Tor biotype (strain Phil 6973). It also contains 300 EU LPS of heat-killed V. cholerae Ogawa classical biotype (Cairo 50); 300 EU LPS of formalin killed V. cholerae Ogawa classical biotype (Cairo 50); 300 EU LPS of heat-killed V. cholerae Inaba, classical biotype (Cairo 48); and 600 EU LPS of formalin killed V. cholerae O139 (4260B) (9). The vaccine has no detectable cholera toxin. Vaccine is packaged as liquid formulations in 1.5-ml doses. No buffer is needed for administered.This vaccine is licensed in India and WHO prequalified.
Study: NCT00983346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be administered as a 3-5 second bolus IV injection at the dose of 0.7 mg/m2 on days 1, 8, 15, and 22 of each 42 day cycle.~Patients will undergo nine 42-day cycles. At the end of this (day 378), patients will be assessed for bone remodeling changes. Evaluation for toxicities will be evaluated at the beginning of each cycle.
Study: NCT01575821

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eucalyptus honey
Description: Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Labiatae honey
Description: Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citrus honey
Description: Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Silan date extract
Description: Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.
Study: NCT01363375

Intervention type: PROCEDURE
Intervention: Foot orthosis, footwear
Description: flat insole, total contact insole , carbon fiber plate; general shoe and rocker sole shoe

Intervention type: PROCEDURE
Intervention: Foot orthosis, Footwear
Description: flat insole, total contact insole, carbon fiber plate; general shoe and rocker sole shoe

Intervention type: PROCEDURE
Intervention: Foot orthosis, footwear
Description: flat insole, total contact insole, carbon fiber plate; general shoe and rocker sole shoe
Study: NCT02050438

Intervention type: PROCEDURE
Intervention: Total Knee Arthroplasty
Study: NCT01286675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: oral eltrombopag, 50 mg, 100 mg, 150 mg, days 2-15
Study: NCT04623346

Intervention type: PROCEDURE
Intervention: Observation for study group
Description: Patients with Weber B-type Ankle fractures, extraarticular wrist fractures and proximal humerus fractures were followed with conservative manner( cast or sling)

Intervention type: PROCEDURE
Intervention: Observation for study group
Description: Patients with Weber B-type Ankle fractures, extraarticular wrist fractures and proximal humerus fractures were followed with conservative manner( cast or sling)

Intervention type: PROCEDURE
Intervention: Observation for study group
Description: Patients with Weber B-type Ankle fractures, extraarticular wrist fractures and proximal humerus fractures were followed with conservative manner( cast or sling)
Study: NCT01893996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Patients will be randomized 1:1 to receive either adalimumab or placebo for the first 26 weeks of the trial, and then after a 26 week washout period, will be crossed over into the other arm (either placebo or adalimumab) for weeks 52-78.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03866122

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NTM Monitoring
Description: NTM and a patient monitor will continuously collect temperature for up to 72 hours. Additionally, Bempu and Thermospot may monitor temperature for up to 72 hours.
Study: NCT03796273

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Undergo standard surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Undergo standard surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Given PO
Study: NCT04418791

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Intermittent Fasting followed by Regular Diet
Description: Modified intermittent fasting (MIF) means fasting for 2 non-consecutive days/week. Fasting is defined as consuming less than 500 kcalories in 1 day (in the course of max. 6 hours). After 12 weeks of fasting, a period of 12 weeks with a regular diet follows.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular Diet followed by Modified Intermittent Fasting
Description: Regular diet means subject can eat as usual for 12 weeks. Next, a period of 12 weeks fasting follows: modified intermittent fasting (MIF) means fasting for 2 non-consecutive days/week. Fasting is defined as consuming less than 500 kcalories in 1 day (in the course of max. 6 hours).
Study: NCT04423718

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)
Description: Solution in Vial, intravitreal (IVT) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)
Description: Solution in Vial, intravitreal (IVT) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)
Description: Solution in Vial, intravitreal (IVT) injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)
Description: Solution in Vial, 2 mg, intravitreal (IVT) injection